Critical Role of Skin in Pathogenesis: Bidirectional Crosstalk Between Skin and Multiple Organs

Abstract

The skin, the largest organ in the human body, serves both as a mechanical barrier and an autonomous lymphoid organ, protecting against various environmental threats while maintaining the balance and functionality of multiple bodily systems. This relationship extends beyond the skin itself, involving other organs closely linked to skin homeostasis and related diseases. However, systematic reviews in this area are still lacking. This review seeks to explore this bidirectional communication, with a particular focus on the critical role of the immune system. We present a comprehensive review of the latest evidence, highlighting the fundamental roles of immune cells and cytokines within the skin–organ axis, particularly IL-17A, which appears to interact with nearly all organs, illustrating their interplay and impact on skin health. Additionally, we discuss the implications of these interactions for the design and application of skin-on-a-chip and organ-on-a-chip technologies, emphasizing the importance of understanding these relationships for developing physiologically relevant in vitro models. By providing a comprehensive analysis of these complex interactions, this review establishes a solid theoretical foundation for the prevention, diagnosis, and treatment of diseases associated with the skin–organ axis, particularly regarding immune cells, cytokines, microorganisms, and their metabolites, ultimately aiming to advance research in related fields and offer new insights for clinical applications.

Keywords

communication / cytokines / IL-17A / immune system / organ-on-a-chip / skin

References

[1] R. Sabat, G. B. E. Jemec, Ł. Matusiak, A. B. Kimball, E. Prens, and K. Wolk, “Hidradenitis Suppurativa,” Nature Reviews Disease Primers 6, no. 1 (2020): 18.

[2] I. Gribonika, V. I. Band, L. Chi, et al., “Skin Autonomous Antibody Production Regulates Host-Microbiota Interactions,” Nature 638, no. 8052 (2024): 1043–1053.

[3] T. A. Harris-Tryon and E. A. Grice, “Microbiota and Maintenance of Skin Barrier Function,” Science 376, no. 6596 (2022): 940–945.

[4] L. Marek-Jozefowicz, R. Czajkowski, A. Borkowska, et al., “The Brain-Skin Axis in Psoriasis-Psychological, Psychiatric, Hormonal, and Dermatological Aspects,” International Journal of Molecular Sciences 23, no. 2 (2022): 669.

[5] J. Strobl, L. M. Gail, L. Kleissl, et al., “Human Resident Memory T Cells Exit the Skin and Mediate Systemic Th2-Driven Inflammation,” Journal of Experimental Medicine 218, no. 11 (2021): e20210417.

[6] M. F. Neurath, “Strategies for Targeting Cytokines in Inflammatory Bowel Disease,” Nature Reviews Immunology 24, no. 8 (2024): 559–576.

[7] D. Fang, B. Chen, A. Lescoat, D. Khanna, and R. Mu, “Immune Cell Dysregulation as a Mediator of Fibrosis in Systemic Sclerosis,” Nature Reviews Rheumatology 18, no. 12 (2022): 683–693.

[8] J. G. Rurik, H. Aghajanian, and J. A. Epstein, “Immune Cells and Immunotherapy for Cardiac Injury and Repair,” Circulation Research 128, no. 11 (2021): 1766–1779.

[9] L. L. Cao and J. C. Kagan, “Targeting Innate Immune Pathways for Cancer Immunotherapy,” Immunity 56, no. 10 (2023): 2206–2217.

[10] J. M. Leyva-Castillo, C. Galand, C. Kam, et al., “Mechanical Skin Injury Promotes Food Anaphylaxis by Driving Intestinal Mast Cell Expansion,” Immunity 50, no. 5 (2019): 1262–1275.e4.

[11] H. Zhang, M. Wang, X. Zhao, Y. Wang, X. Chen, and J. Su, “Role of Stress in Skin Diseases: A Neuroendocrine-Immune Interaction View,” Brain, Behavior, and Immunity 116 (2024): 286–302.

[12] Y. Kitagawa, K. Hayakawa, D. Oikawa, et al., “Repeated Restraint Stress Modifies Fatty Acid and Amino Acid Metabolism in the Mouse Skin,” Journal of Veterinary Medical Science 84, no. 4 (2022): 511–519.

[13] J. Yang, S. Zhang, Q. Wu, et al., “T Cell-Mediated Skin-Brain Axis: Bridging the Gap Between Psoriasis and Psychiatric Comorbidities,” Journal of Autoimmunity 144 (2024): 103176.

[14] A. T. Slominski, T. K. Kim, K. Kleszczyński, et al., “Characterization of Serotonin and N-Acetylserotonin Systems in the Human Epidermis and Skin Cells,” Journal of Pineal Research 68, no. 2 (2020): e12626.

[15] J. Moncrieff, R. E. Cooper, T. Stockmann, S. Amendola, M. P. Hengartner, and M. A. Horowitz, “The Serotonin Theory of Depression: A Systematic Umbrella Review of the Evidence,” Molecular Psychiatry 28, no. 8 (2023): 3243–3256.

[16] M. S. Shajib and W. I. Khan, “The Role of Serotonin and Its Receptors in Activation of Immune Responses and Inflammation,” Acta Physiologica 213, no. 3 (2015): 561–574.

[17] M. Shen, D. Cao, Y. Xiao, et al., “Serum 5-Hydroxytryptamine Is Related to Psoriasis Severity in Patients With Comorbid Anxiety or Depression,” Acta Dermato Venereologica 101, no. 8 (2021): adv00514.

[18] S. D'Costa, S. Ayyadurai, A. J. Gibson, et al., “Mast Cell Corticotropin-Releasing Factor Subtype 2 Suppresses Mast Cell Degranulation and Limits the Severity of Anaphylaxis and Stress-Induced Intestinal Permeability,” Journal of Allergy and Clinical Immunology 143, no. 5 (2019): 1865–1877.e4.

[19] K. Gupta and I. T. Harvima, “Mast Cell-Neural Interactions Contribute to Pain and Itch,” Immunological Reviews 282, no. 1 (2018): 168–187.

[20] E. Hendriksen, D. van Bergeijk, R. S. Oosting, and F. A. Redegeld, “Mast Cells in Neuroinflammation and Brain Disorders,” Neuroscience & Biobehavioral Reviews 79 (2017): 119–133.

[21] M. A. Rosenkranz, R. J. Davidson, D. G. Maccoon, J. F. Sheridan, N. H. Kalin, and A. Lutz, “A Comparison of Mindfulness-Based Stress Reduction and an Active Control in Modulation of Neurogenic Inflammation,” Brain, Behavior, and Immunity 27, no. 1 (2013): 174–184.

[22] M. Steinhoff, F. Ahmad, A. Pandey, et al., “Neuroimmune Communication Regulating Pruritus in Atopic Dermatitis,” Journal of Allergy and Clinical Immunology 149, no. 6 (2022): 1875–1898.

[23] Y. Zhang, H. Zhang, B. Jiang, X. Tong, S. Yan, and J. Lu, “Current Views on Neuropeptides in Atopic Dermatitis,” Experimental Dermatology 30, no. 11 (2021): 1588–1597.

[24] C. H. Flayer and C. L. Sokol, “Sensory Neurons Control the Functions of Dendritic Cells to Guide Allergic Immunity,” Current Opinion in Immunology 74 (2022): 85–91.

[25] J. Pan, L. Zhang, X. Wang, et al., “Chronic Stress Induces Pulmonary Epithelial Cells to Produce Acetylcholine That Remodels Lung Pre-Metastatic Niche of Breast Cancer by Enhancing Netosis,” Journal of Experimental & Clinical Cancer Research 42, no. 1 (2023): 255.

[26] N. Acharya, A. Madi, H. Zhang, et al., “Endogenous Glucocorticoid Signaling Regulates CD8(+) T Cell Differentiation and Development of Dysfunction in the Tumor Microenvironment,” Immunity 53, no. 3 (2020): 658–671.e6.

[27] A. Sommershof, L. Scheuermann, J. Koerner, and M. Groettrup, “Chronic Stress Suppresses Anti-Tumor T(CD8+) Responses and Tumor Regression Following Cancer Immunotherapy in a Mouse Model of Melanoma,” Brain, Behavior, and Immunity 65 (2017): 140–149.

[28] L. Quatrini, E. Wieduwild, B. Escaliere, et al., “Endogenous Glucocorticoids Control Host Resistance to Viral Infection Through the Tissue-Specific Regulation of PD-1 Expression on NK Cells,” Nature Immunology 19, no. 9 (2018): 954–962.

[29] F. S. Dhabhar, A. N. Saul, C. Daugherty, T. H. Holmes, D. M. Bouley, and T. M. Oberyszyn, “Short-Term Stress Enhances Cellular Immunity and Increases Early Resistance to Squamous Cell Carcinoma,” Brain, Behavior, and Immunity 24, no. 1 (2010): 127–137.

[30] P. T. Rudak, J. Choi, K. M. Parkins, et al., “Chronic Stress Physically Spares but Functionally Impairs Innate-Like Invariant T Cells,” Cell Reports 35, no. 2 (2021): 108979.

[31] A. N. Saul, T. M. Oberyszyn, C. Daugherty, et al., “Chronic Stress and Susceptibility to Skin Cancer,” Journal of the National Cancer Institute 97, no. 23 (2005): 1760–1767.

[32] C. P. Fagundes, R. Glaser, S. L. Johnson, et al., “Basal Cell Carcinoma: Stressful Life Events and the Tumor Environment,” Archives of General Psychiatry 69, no. 6 (2012): 618–626.

[33] X. Huang, B. Hussain, and J. Chang, “Peripheral Inflammation and Blood-Brain Barrier Disruption: Effects and Mechanisms,” CNS Neuroscience & Therapeutics 27, no. 1 (2021): 36–47.

[34] Q. Zhao, J. Yu, H. Zhou, et al., “Intestinal Dysbiosis Exacerbates the Pathogenesis of Psoriasis-Like Phenotype Through Changes in Fatty Acid Metabolism,” Signal Transduction and Targeted Therapy 8, no. 1 (2023): 40.

[35] C. Schiweck, M. Valles-Colomer, V. Arolt, et al., “Depression and Suicidality: A Link to Premature T Helper Cell Aging and Increased Th17 Cells,” Brain, Behavior, and Immunity 87 (2020): 603–609.

[36] L. Y. Al-Ayadhi and G. A. Mostafa, “Elevated Serum Levels of Interleukin-17A in Children With Autism,” Journal of Neuroinflammation 9 (2012): 595.

[37] Z. Peng, S. Peng, K. Lin, et al., “Chronic Stress-Induced Depression Requires the Recruitment of Peripheral Th17 Cells Into the Brain,” Journal of Neuroinflammation 19, no. 1 (2022): 186.

[38] H. Kebir, K. Kreymborg, I. Ifergan, et al., “Human TH17 Lymphocytes Promote Blood-Brain Barrier Disruption and Central Nervous System Inflammation,” Nature Medicine 13, no. 10 (2007): 1173–1175.

[39] R. Kumar, A. L. Theiss, and K. Venuprasad, “RORγt Protein Modifications and IL-17-Mediated Inflammation,” Trends in Immunology 42, no. 11 (2021): 1037–1050.

[40] X. Zhang, M. Monnoye, M. Mariadassou, et al., “Glucose but Not Fructose Alters the Intestinal Paracellular Permeability in Association With Gut Inflammation and Dysbiosis in Mice,” Frontiers in Immunology 12 (2021): 635076.

[41] N. Moriyama, M. Saito, Y. Ono, et al., “Increased Interleukin-17-Producing Gammadelta T Cells in the Brain Exacerbate the Pathogenesis of Sepsis-Associated Encephalopathy and Sepsis-Induced Anxiety in Mice,” Journal of Clinical Medicine 12, no. 13 (2023): 4309.

[42] L. H. Anane, K. M. Edwards, V. E. Burns, et al., “Mobilization of γδ T Lymphocytes in Response to Psychological Stress, Exercise, and β-Agonist Infusion,” Brain, Behavior, and Immunity 23, no. 6 (2009): 823–829.

[43] K. Alves de Lima, J. Rustenhoven, S. Da Mesquita, et al., “Meningeal γδ T Cells Regulate Anxiety-Like Behavior via IL-17a Signaling in Neurons,” Nature Immunology 21, no. 11 (2020): 1421–1429.

[44] J. F. Schlaak, M. Buslau, W. Jochum, et al., “T Cells Involved in Psoriasis Vulgaris Belong to the Th1 Subset,” Journal of Investigative Dermatology 102, no. 2 (1994): 145–149.

[45] K. Kahl, “Expression of Tumor Necrosis Factor-α and Interferon-γ mRNA in Blood Cells Correlates With Depression Scores During an Acute Attack in Patients With Multiple Sclerosis,” Psychoneuroendocrinology 27, no. 6 (2002): 671–681.

[46] A. Inserra, C. A. Mastronardi, G. Rogers, J. Licinio, and M. L. Wong, “Neuroimmunomodulation in Major Depressive Disorder: Focus on Caspase 1, Inducible Nitric Oxide Synthase, and Interferon-Gamma,” Molecular Neurobiology 56, no. 6 (2019): 4288–4305.

[47] H. Wen, J. Tan, M. Tian, Y. Wang, Y. Gao, and Y. Gong, “TGF-β1 Ameliorates BBB Injury and Improves Long-Term Outcomes in Mice After ICH,” Biochemical and Biophysical Research Communications 654 (2023): 136–144.

[48] F. Li, Y. Lan, Y. Wang, et al., “Endothelial Smad4 Maintains Cerebrovascular Integrity by Activating N-Cadherin Through Cooperation With Notch,” Developmental Cell 20, no. 3 (2011): 291–302.

[49] B. Barabási, L. Barna, A. R. Santa-Maria, et al., “Role of Interleukin-6 and Interleukin-10 in Morphological and Functional Changes of the Blood-Brain Barrier in Hypertriglyceridemia,” Fluids and Barriers of the CNS 20, no. 1 (2023): 15.

[50] W. Tao, G. Zhang, C. Liu, L. Jin, X. Li, and S. Yang, “Low-Dose LPS Alleviates Early Brain Injury After Sah by Modulating Microglial M1/M2 Polarization via USP19/FOXO1/IL-10/IL-10R1 Signaling,” Redox Biology 66 (2023): 102863.

[51] K. O. Shin, D. A. Crumrine, S. Kim, et al., “Phenotypic Overlap Between Atopic Dermatitis and Autism,” BMC Neuroscience 22, no. 1 (2021): 43.

[52] K. J. Blake, P. Baral, T. Voisin, et al., “Staphylococcus aureus Produces Pain Through Pore-Forming Toxins and Neuronal TRPV1 That Is Silenced by Qx-314,” Nature Communications 9, no. 1 (2018): 37.

[53] S. W. Kashem, M. S. Riedl, C. Yao, C. N. Honda, L. Vulchanova, and D. H. Kaplan, “Nociceptive Sensory Fibers Drive Interleukin-23 Production From CD301b+ Dermal Dendritic Cells and Drive Protective Cutaneous Immunity,” Immunity 43, no. 3 (2015): 515–526.

[54] F. A. Pinho-Ribeiro, B. Baddal, R. Haarsma, et al., “Blocking Neuronal Signaling to Immune Cells Treats Streptococcal Invasive Infection,” Cell 173, no. 5 (2018): 1083–1097.

[55] M. R. Mahmud, S. Akter, S. K. Tamanna, et al., “Impact of Gut Microbiome on Skin Health: Gut-Skin Axis Observed Through the Lenses of Therapeutics and Skin Diseases,” Gut Microbes 14, no. 1 (2022): 2096995.

[56] Z. Fang, T. Pan, L. Li, et al., “Bifidobacterium Longum Mediated Tryptophan Metabolism to Improve Atopic Dermatitis via the Gut-Skin Axis,” Gut Microbes 14, no. 1 (2022): 2044723.

[57] W. K. Kim, Y. J. Jang, D. H. Han, et al., “Lactobacillus paracasei KBL382 Administration Attenuates Atopic Dermatitis by Modulating Immune Response and Gut Microbiota,” Gut Microbes 12, no. 1 (2020): 1819156.

[58] G. J. Silverman, D. F. Azzouz, N. Gisch, and A. Amarnani, “The Gut Microbiome in Systemic Lupus Erythematosus: Lessons From Rheumatic Fever,” Nature Reviews Rheumatology 20, no. 3 (2024): 143–157.

[59] C. Hoskinson, M. V. Medeleanu, M. E. Reyna, et al., “Antibiotics Taken Within the First Year of Life Are Linked to Infant Gut Microbiome Disruption and Elevated Atopic Dermatitis Risk,” Journal of Allergy and Clinical Immunology 154, no. 1 (2024): 131–142.

[60] C. Dai and Y. H. Huang, “Diagnostic Dilemma: Sudden Onset of Multiple Skin Lesions in a Patient With Intestinal Disease,” Gut 74, no. 5 (2024): 705–839.

[61] J. H. Kim, K. Kim, and W. Kim, “Gut Microbiota Restoration Through Fecal Microbiota Transplantation: A New Atopic Dermatitis Therapy,” Experimental & Molecular Medicine 53, no. 5 (2021): 907–916.

[62] E. N. Baruch, I. Youngster, G. Ben-Betzalel, et al., “Fecal Microbiota Transplant Promotes Response in Immunotherapy-Refractory Melanoma Patients,” Science 371, no. 6529 (2021): 602–609.

[63] A. Schwarz, R. Philippsen, and T. Schwarz, “Induction of Regulatory T Cells and Correction of Cytokine Disbalance by Short-Chain Fatty Acids: Implications for Psoriasis Therapy,” Journal of Investigative Dermatology 141, no. 1 (2021): 95–104.e2.

[64] H. J. Kim, S. H. Lee, and S. J. Hong, “Antibiotics-Induced Dysbiosis of Intestinal Microbiota Aggravates Atopic Dermatitis in Mice by Altered Short-Chain Fatty Acids,” Allergy, Asthma & Immunology Research 12, no. 1 (2020): 137–148.

[65] A. De Benedetto, N. M. Rafaels, L. Y. McGirt, et al., “Tight Junction Defects in Patients With Atopic Dermatitis,” Journal of Allergy and Clinical Immunology 127, no. 3 (2011): 773-786.e1-7.

[66] M. Gio-Batta, F. Sjöberg, K. Jonsson, et al., “Fecal Short Chain Fatty Acids in Children Living on Farms and a Link Between Valeric Acid and Protection From Eczema,” Scientific Reports 10, no. 1 (2020): 22449.

[67] M. Gio-Batta, K. Spetz, M. Barman, et al., “Low Concentration of Fecal Valeric Acid at 1 Year of Age Is Linked With Eczema and Food Allergy at 13 Years of Age: Findings From a Swedish Birth Cohort,” International Archives of Allergy and Immunology 183, no. 4 (2022): 398–408.

[68] T. Dokoshi, Y. Chen, K. J. Cavagnero, et al., “Dermal Injury Drives a Skin to Gut Axis That Disrupts the Intestinal Microbiome and Intestinal Immune Homeostasis in Mice,” Nature Communications 15, no. 1 (2024): 3009.

[69] Z. C. Chiesa Fuxench, J. Wan, S. Wang, et al., “Risk of Inflammatory Bowel Disease in Patients With Atopic Dermatitis,” JAMA Dermatology 159, no. 10 (2023): 1085–1092.

[70] Y. Fu, C. H. Lee, and C. C. Chi, “Association of Psoriasis With Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis,” JAMA Dermatology 154, no. 12 (2018): 1417–1423.

[71] H. A. Eckermann, J. Meijer, K. Cooijmans, L. Lahti, and C. de Weerth, “Daily Skin-to-Skin Contact Alters Microbiota Development in Healthy Full-Term Infants,” Gut Microbes 16, no. 1 (2024): 2295403.

[72] L. C. Conteville and A. C. P. Vicente, “Skin Exposure to Sunlight: A Factor Modulating the Human Gut Microbiome Composition,” Gut Microbes 11, no. 5 (2020): 1135–1138.

[73] K. Minton, “Scratching out a Skin-Gut Pathway,” Nature Reviews Immunology 19, no. 6 (2019): 350–351.

[74] H. Kiyohara, T. Sujino, T. Teratani, et al., “Toll-Like Receptor 7 Agonist-Induced Dermatitis Causes Severe Dextran Sulfate Sodium Colitis by Altering the Gut Microbiome and Immune Cells,” Cellular and Molecular Gastroenterology and Hepatology 7, no. 1 (2019): 135–156.

[75] L. Ouchene, A. Muntyanu, D. Assayag, et al., “Skin Disorders and Interstitial Lung Disease: Part II—The Spectrum of Cutaneous Diseases With Lung Disease Association,” Journal of the American Academy of Dermatology 88, no. 4 (2023): 767–782.

[76] M. Wijsenbeek and V. Cottin, “Spectrum of Fibrotic Lung Diseases,” New England Journal of Medicine 383, no. 10 (2020): 958–968.

[77] C. Rolfo, A. F. Cardona, A. Ruiz-Patiño, et al., “Atypical Skin Manifestations During Immune Checkpoint Blockage in Coronavirus Disease 2019-Infected Patients With Lung Cancer,” Journal of Thoracic Oncology 15, no. 11 (2020): 1767–1772.

[78] Q. Luo, J. Chen, L. Qin, et al., “Psoriasis May Increase the Risk of Lung Cancer: A Two-Sample Mendelian Randomization Study,” Journal of the European Academy of Dermatology and Venereology 36, no. 11 (2022): 2113–2119.

[79] S. Vaengebjerg, L. Skov, A. Egeberg, and N. D. Loft, “Prevalence, Incidence, and Risk of Cancer in Patients With Psoriasis and Psoriatic Arthritis: A Systematic Review and Meta-Analysis,” JAMA Dermatology 156, no. 4 (2020): 421–429.

[80] S. Manzoor, N. Mariappan, I. Zafar, et al., “Cutaneous Lewisite Exposure Causes Acute Lung Injury,” Annals of the New York Academy of Sciences 1479, no. 1 (2020): 210–222.

[81] S. P. Saunders, A. Floudas, T. Moran, et al., “Dysregulated Skin Barrier Function in Tmem79 Mutant Mice Promotes IL-17A-dependent Spontaneous Skin and Lung Inflammation,” Allergy 75, no. 12 (2020): 3216–3227.

[82] J. Deckers, N. Bougarne, V. Mylka, et al., “Co-Activation of Glucocorticoid Receptor and Peroxisome Proliferator-Activated Receptor-γ in Murine Skin Prevents Worsening of Atopic March,” Journal of Investigative Dermatology 138, no. 6 (2018): 1360–1370.

[83] G. J. Patrick, H. Liu, M. P. Alphonse, et al., “Epicutaneous Staphylococcus aureus Induces IL-36 to Enhance IgE Production and Ensuing Allergic Disease,” Journal of Clinical Investigation 131, no. 5 (2021): e143334.

[84] S. K. Bantz, Z. Zhu, and T. Zheng, “The Atopic March: Progression From Atopic Dermatitis to Allergic Rhinitis and Asthma,” Journal of Clinical & Cellular Immunology 5, no. 2 (2014): 202.

[85] S. Wenzel, L. Ford, D. Pearlman, et al., “Dupilumab in Persistent Asthma With Elevated Eosinophil Levels,” New England Journal of Medicine 368, no. 26 (2013): 2455–2466.

[86] S. Naik, N. Bouladoux, C. Wilhelm, et al., “Compartmentalized Control of Skin Immunity by Resident Commensals,” Science 337, no. 6098 (2012): 1115–1119.

[87] M. Mleczko, A. Gerkowicz, and D. Krasowska, “Chronic Inflammation as the Underlying Mechanism of the Development of Lung Diseases in Psoriasis: A Systematic Review,” International Journal of Molecular Sciences 23, no. 3 (2022): 1767.

[88] M. Polastri, E. M. Clini, S. Nava, and N. Ambrosino, “Manual Massage Therapy for Patients With COPD: A Scoping Review,” Medicina 55, no. 5 (2019): 151.

[89] B. Terziroli beretta-Piccoli, P. Invernizzi, M. E. Gershwin, and C. Mainetti, “Skin Manifestations Associated With Autoimmune Liver Diseases: A Systematic Review,” Clinical Reviews in Allergy & Immunology 53, no. 3 (2017): 394–412.

[90] J. J. Yang, K. A. Nguyen, M. W. Fleischman, O. Aly, and K. Cheng, “Psoriasis in Liver Disease: Associations Beyond Nonalcoholic Fatty Liver Disease,” Journal of the American Academy of Dermatology 86, no. 4 (2022): 883–885.

[91] P. Jensen, A. Egeberg, G. Gislason, P. R. Hansen, J. P. Thyssen, and L. Skov, “Increased Risk of Autoimmune Hepatitis in Patients With Psoriasis: A Danish Nationwide Cohort Study,” Journal of Investigative Dermatology 136, no. 7 (2016): 1515–1517.

[92] Z. Ruan, T. Lu, Y. Chen, et al., “Association Between Psoriasis and Nonalcoholic Fatty Liver Disease Among Outpatient US Adults,” JAMA Dermatology 158, no. 7 (2022): 745–753.

[93] A. Olveira, P. Herranz, and M. L. Montes, “Psoriasis and Fatty Liver: A Harmful Synergy,” Revista Española de Enfermedades Digestivas 111, no. 4 (2019): 314–319.

[94] P. Vasseur, M. Pohin, J. F. Jégou, et al., “Liver Fibrosis Is Associated With Cutaneous Inflammation in the Imiquimod-Induced Murine Model of Psoriasiform Dermatitis,” British Journal of Dermatology 179, no. 1 (2018): 101–109.

[95] S. Imafuku, R. Naito, and J. Nakayama, “Possible Association of Hepatitis C Virus Infection With Late-Onset Psoriasis: A Hospital-Based Observational Study,” Journal of Dermatology 40, no. 10 (2013): 813–818.

[96] R. Teshima, N. Saito-Sasaki, and Y. Sawada, “Generalized Pustular Psoriasis and Systemic Organ Dysfunctions,” International Journal of Molecular Sciences 25, no. 11 (2024): 6270.

[97] A. Olveira, S. Augustin, S. Benlloch, et al., “The Essential Role of IL-17 as the Pathogenetic Link Between Psoriasis and Metabolic-Associated Fatty Liver Disease,” Life 13, no. 2 (2023): 419.

[98] H. Nakajima, K. Nakajima, M. Takaishi, et al., “The Skin–Liver Axis Modulates the Psoriasiform Phenotype and Involves Leucine-Rich α-2 Glycoprotein,” Journal of Immunology 206, no. 7 (2021): 1469–1477.

[99] T. Naka and M. Fujimoto, “LRG Is a Novel Inflammatory Marker Clinically Useful for the Evaluation of Disease Activity in Rheumatoid Arthritis and Inflammatory Bowel Disease,” Immunological Medicine 41, no. 2 (2018): 62–67.

[100] J. Takeshita, S. Grewal, S. M. Langan, et al., “Psoriasis and Comorbid Diseases,” Journal of the American Academy of Dermatology 76, no. 3 (2017): 377–390.

[101] P. Gisondi, F. Bellinato, G. Girolomoni, and C. Albanesi, “Pathogenesis of Chronic Plaque Psoriasis and Its Intersection With Cardio-Metabolic Comorbidities,” Frontiers in Pharmacology 11 (2020): 117.

[102] A. Egeberg, P. Gisondi, J. M. Carrascosa, R. B. Warren, and U. Mrowietz, “The Role of the Interleukin-23/Th17 Pathway in Cardiometabolic Comorbidity Associated With Psoriasis,” Journal of the European Academy of Dermatology and Venereology 34, no. 8 (2020): 1695–1706.

[103] M. Y. Hu, Q. Yang, and J. Zheng, “The Association of Psoriasis and Hypertension: Focusing on Anti-Inflammatory Therapies and Immunological Mechanisms,” Clinical and Experimental Dermatology 45, no. 7 (2020): 836–840.

[104] J. Upadhyay, O. Farr, N. Perakakis, W. Ghaly, and C. Mantzoros, “Obesity as a Disease,” Medical Clinics of North America 102, no. 1 (2018): 13–33.

[105] H. Ohbe, M. Iwagami, Y. Sasabuchi, and H. Yasunaga, “Increased Risk of Infective Endocarditis After Traumatic Skin Wound,” Heart 107, no. 23 (2021): 1868–1874.

[106] M. Goldenberg, M. Reynolds, S. Smart, J. Kaffenberger, S. V. Raman, and B. H. Kaffenberger, “A Retrospective Study of Myocardial Abnormalities Detected on Cardiac Magnetic Resonance Imaging Among Patients With Psoriasis Compared to Inflammatory Skin Disease Controls,” Journal of the European Academy of Dermatology and Venereology 34, no. 10 (2020): e606–e608.

[107] S. Hu and C. C. E. Lan, “Psoriasis and Cardiovascular Comorbidities: Focusing on Severe Vascular Events, Cardiovascular Risk Factors and Implications for Treatment,” International Journal of Molecular Sciences 18, no. 10 (2017): 2211.

[108] A. Sato, Y. Sato, F. Shimada, and Y. Torigata, “Varying Changes in Heart Rate Produced by Nociceptive Stimulation of the Skin in Rats at Different Temperatures,” Brain Research 110, no. 2 (1976): 301–311.

[109] A. Cartron and M. S. Driscoll, “Comorbidities of Hidradenitis Suppurativa: A Review of the Literature,” International Journal of Women's Dermatology 5, no. 5 (2019): 330–334.

[110] V. De Vita and P. R. Hansen, “Interleukin-32 May Contribute to Increased Risk of Cardiovascular Disease in Patients With Hidradenitis Suppurativa,” Atherosclerosis 267 (2017): 175.

[111] B. Herrero-Fernandez, R. Gomez-Bris, B. Somovilla-Crespo, and J. M. Gonzalez-Granado, “Immunobiology of Atherosclerosis: A Complex Net of Interactions,” International Journal of Molecular Sciences 20, no. 21 (2019): 5293.

[112] R. Dey-Rao and A. A. Sinha, “Genome-Wide Transcriptional Profiling of Chronic Cutaneous Lupus Erythematosus (CCLE) Peripheral Blood Identifies Systemic Alterations Relevant to the Skin Manifestation,” Genomics 105, no. 2 (2015): 90–100.

[113] K. Masek-Hammerman, E. Peeva, A. Ahmad, et al., “Monoclonal Antibody Against Macrophage Colony-Stimulating Factor Suppresses Circulating Monocytes and Tissue Macrophage Function but Does Not Alter Cell Infiltration/Activation in Cutaneous Lesions or Clinical Outcomes in Patients With Cutaneous Lupus Erythematosus,” Clinical and Experimental Immunology 183, no. 2 (2016): 258–270.

[114] M. J. Smogorzewski, “Skin Blood Flow and Vascular Endothelium Function in Uremia,” Journal of Renal Nutrition 27, no. 6 (2017): 465–469.

[115] E. Wojtowicz-Prus, K. Kilis-Pstrusinska, A. Reich, et al., “Disturbed Skin Barrier in Children With Chronic Kidney Disease,” Pediatric Nephrology 30, no. 2 (2015): 333–338.

[116] K. Abuabara, R. S. Azfar, D. B. Shin, A. L. Neimann, A. B. Troxel, and J. M. Gelfand, “Cause-Specific Mortality in Patients With Severe Psoriasis: A Population-Based Cohort Study in the U.K.,” British Journal of Dermatology 163, no. 3 (2010): 586–592.

[117] A. Svedbom, J. Dalén, C. Mamolo, et al., “Increased Cause-Specific Mortality in Patients With Mild and Severe Psoriasis: A Population-Based Swedish Register Study,” Acta Dermato-Venereologica 95, no. 7 (2015): 809–815.

[118] J. Wan, S. Wang, K. Haynes, M. R. Denburg, D. B. Shin, and J. M. Gelfand, “Risk of Moderate to Advanced Kidney Disease in Patients With Psoriasis: Population Based Cohort Study,” BMJ 347 (2013): f5961.

[119] S. Skopelja-Gardner, J. Tai, X. Sun, et al., “Acute Skin Exposure to Ultraviolet Light Triggers Neutrophil-Mediated Kidney Inflammation,” Proceedings of the National Academy of Sciences 118, no. 3 (2021): e2019097118.

[120] A. G. A. Kolios and G. C. Tsokos, “Skin-Kidney Crosstalk in SLE,” Nature Reviews Rheumatology 17, no. 5 (2021): 253–254.

[121] H. Terui, K. Yamasaki, M. Wada-Irimada, et al., “Staphylococcus aureus Skin Colonization Promotes SLE-Like Autoimmune Inflammation via Neutrophil Activation and the IL-23/IL-17 Axis,” Science Immunology 7, no. 76 (2022): eabm9811.

[122] S. Zhai, D. Liu, H. Liu, et al., “Cold Atmospheric Plasma for Chronic Kidney Disease-Related Skin Disorders,” Nephrology Dialysis Transplantation 39, no. 11 (2024): 1817–1834.

[123] Y. L. Lin, C. L. Wang, K. L. Liu, C. N. Yeh, and T. I. Chiang, “Omega-3 Fatty Acids Improve Chronic Kidney Disease-Associated Pruritus and Inflammation,” Medicina 58, no. 6 (2022): 796.

[124] M. C. K. Severinsen and B. K. Pedersen, “Muscle-Organ Crosstalk: The Emerging Roles of Myokines,” Endocrine Reviews 41, no. 4 (2020): 594–609.

[125] B. Zou, J. Du, Q. Xuan, et al., “Scraping Therapy Improved Muscle Regeneration Through Regulating GLUT4/Glycolytic and AMPK/mTOR/4EBP1 Pathways in Rats With Lumbar Multifidus Injury,” Pain Research and Management 2023 (2023): 8870256.

[126] M. Qian, L. Qin, and H. Guan, “A Case of Muscle Twitching With Psoriasis,” JAMA Neurology 76, no. 9 (2019): 1119–1120.

[127] A. Rendon and K. Schäkel, “Psoriasis Pathogenesis and Treatment,” International Journal of Molecular Sciences 20, no. 6 (2019): 1475.

[128] L. Kao, L. Chung, and D. F. Fiorentino, “Pathogenesis of Dermatomyositis: Role of Cytokines and Interferon,” Current Rheumatology Reports 13, no. 3 (2011): 225–232.

[129] C. E. M. Griffiths, A. W. Armstrong, J. E. Gudjonsson, and J. N. W. N. Barker, “Psoriasis,” Lancet 397, no. 10281 (2021): 1301–1315.

[130] Ö. Uluçkan and E. F. Wagner, “Role of IL-17A Signalling in Psoriasis and Associated Bone Loss,” Clinical and Experimental Rheumatology 34, no. 4 Suppl 98 (2016): 17–20.

[131] Ö. Uluçkan, M. Jimenez, S. Karbach, et al., “Chronic Skin Inflammation Leads to Bone Loss by IL-17-Mediated Inhibition of Wnt Signaling in Osteoblasts,” Science Translational Medicine 8, no. 330 (2016): 330ra37.

[132] A. Raimondo, S. Lembo, R. Di Caprio, et al., “Psoriatic Cutaneous Inflammation Promotes Human Monocyte Differentiation Into Active Osteoclasts, Facilitating Bone Damage,” European Journal of Immunology 47, no. 6 (2017): 1062–1074.

[133] N. H. Ravn, Z. F. Ahmadzay, T. A. Christensen, et al., “Bidirectional Association Between Atopic Dermatitis, Conjunctivitis, and Other Ocular Surface Diseases: A Systematic Review and Meta-Analysis,” Journal of the American Academy of Dermatology 85, no. 2 (2021): 453–461.

[134] A. Ruggiero, G. Fabbrocini, S. Cacciapuoti, E. Cinelli, L. Gallo, and M. Megna, “Ocular Manifestations in Psoriasis Screening (OcMaPS) Questionnaire: A Useful Tool to Reveal Misdiagnosed Ocular Involvement in Psoriasis,” Journal of Clinical Medicine 10, no. 5 (2021): 1031.

[135] J. E. Weinstein and K. L. Pepple, “Cytokines in Uveitis,” Current Opinion in Ophthalmology 29, no. 3 (2018): 267–274.

[136] C. Fotiadou and E. Lazaridou, “Psoriasis and Uveitis: Links and Risks,” Psoriasis 9 (2019): 91–96.

[137] B. Rehal, B. S. Modjtahedi, L. S. Morse, I. R. Schwab, and H. I. Maibach, “Ocular Psoriasis,” Journal of the American Academy of Dermatology 65, no. 6 (2011): 1202–1212.

[138] L. A. Low, C. Mummery, B. R. Berridge, C. P. Austin, and D. A. Tagle, “Organs-on-Chips: Into the Next Decade,” Nature Reviews Drug Discovery 20, no. 5 (2021): 345–361.

[139] R. S. N. Tavares, T. P. Tao, I. Maschmeyer, et al., “Toxicity of Topically Applied Drugs Beyond Skin Irritation: Static Skin Model Vs. Two Organs-on-a-Chip,” International Journal of Pharmaceutics 589 (2020): 119788.

[140] I. Risueno, L. Valencia, J. L. Jorcano, and D. Velasco, “Skin-on-a-Chip Models: General Overview and Future Perspectives,” APL Bioeng 5, no. 3 (2021): 030901.

[141] R. Janssen, J. W. M. de Kleer, B. Heming, et al., “Food Allergen Sensitization on a Chip: The Gut-Immune-Skin Axis,” Trends in Biotechnology 42, no. 1 (2024): 119–134.

[142] N. Ismayilzada, C. Tarar, S. R. Dabbagh, et al., “Skin-on-a-Chip Technologies Towards Clinical Translation and Commercialization,” Biofabrication 16, no. 4 (2024): 042001.

[143] K. R. Shah, L. Garriga-Cerda, A. Pappalardo, et al., “A Biopsy-Sized 3D Skin Model With a Perifollicular Vascular Plexus Enables Studying Immune Cell Trafficking in the Skin,” Biofabrication 16, no. 4 (2024): 045006.

[144] D. E. Ingber, “Human Organs-on-Chips for Disease Modelling, Drug Development and Personalized Medicine,” Nature Reviews Genetics 23, no. 8 (2022): 467–491.

[145] E. W. Esch, A. Bahinski, and D. Huh, “Organs-on-Chips at the Frontiers of Drug Discovery,” Nature Reviews Drug Discovery 14, no. 4 (2015): 248–260.

[146] M. Baker, “A Living System on a Chip,” Nature 471, no. 7340 (2011): 661–665.

[147] K. G. Birmingham, M. J. O'Melia, S. Bordy, et al., “Lymph Node Subcapsular Sinus Microenvironment-on-a-Chip Modeling Shear Flow Relevant to Lymphatic Metastasis and Immune Cell Homing,” iScience 23, no. 11 (2020): 101751.

[148] A. Shanti, B. Samara, A. Abdullah, et al., “Multi-Compartment 3D-Cultured Organ-on-a-Chip: Towards a Biomimetic Lymph Node for Drug Development,” Pharmaceutics 12, no. 5 (2020): 464.

[149] D. B. Chou, V. Frismantas, Y. Milton, et al., “On-Chip Recapitulation of Clinical Bone Marrow Toxicities and Patient-Specific Pathophysiology,” Nature Biomedical Engineering 4, no. 4 (2020): 394–406.

[150] K. Ronaldson-Bouchard, D. Teles, K. Yeager, et al., “A Multi-Organ Chip With Matured Tissue Niches Linked by Vascular Flow,” Nature Biomedical Engineering 6, no. 4 (2022): 351–371.

[151] N. Mizutani, C. Sae-Wong, S. Kangsanant, T. Nabe, and S. Yoshino, “Thymic Stromal Lymphopoietin-Induced Interleukin-17A Is Involved in the Development of IgE-Mediated Atopic Dermatitis-Like Skin Lesions in Mice,” Immunology 146, no. 4 (2015): 568–581.

[152] S. Inan, J. J. Meissler, S. Bessho, et al., “Blocking IL-17A Prevents Oxycodone-Induced Depression-Like Effects and Elevation of IL-6 Levels in the Ventral Tegmental Area and Reduces Oxycodone-Derived Physical Dependence in Rats,” Brain, Behavior, and Immunity 117 (2024): 100–111.

[153] H. L. Guo, X. R. Shen, X. T. Liang, and L. Z. Li, “The Role of Autophagy-Related Proteins in the Pathogenesis of Neuromyelitis Optica Spectrum Disorders,” Bioengineered 13, no. 6 (2022): 14329–14338.

[154] Q. Dai, S. Han, T. Liu, et al., “IL-17A Neutralization Improves the Neurological Outcome of Mice With Ischemic Stroke and Inhibits Caspase-12-Dependent Apoptosis,” Frontiers in Aging Neuroscience 12 (2020): 274.

[155] L. Ma, X. Pan, F. Zhou, K. Liu, and L. Wang, “Hyperforin Protects Against Acute Cerebral Ischemic Injury Through Inhibition of Interleukin-17A-Mediated Microglial Activation,” Brain Research 1678 (2018): 254–261.

[156] M. Zhang, X. Fei, G. Zhang, et al., “Role of Neutralizing Anti-Murine Interleukin-17A Monoclonal Antibody on Chronic Ozone-Induced Airway Inflammation in Mice,” Biomedicine & Pharmacotherapy 83 (2016): 247–256.

[157] Y. Zhang, X. Li, M. He, et al., “The Effects of Neutralizing Anti-Murine Interleukin-17A Monoclonal Antibody on Ozone-Induced Inflammation and Glucocorticoids Insensitivity in a Murine Model of Asthma,” Biomedicine & Pharmacotherapy 114 (2019): 108786.

[158] M. T. Mize, X. L. Sun, and J. W. Simecka, “Interleukin-17A Exacerbates Disease Severity In BALB/C Mice Susceptible to Lung Infection With Mycoplasma Pulmonis,” Infection and Immunity 86, no. 9 (2018): e00292-18.

[159] C. Klemann, A. Schröder, A. Dreier, et al., “Interleukin 17, Produced by γδ T Cells, Contributes to Hepatic Inflammation in a Mouse Model of Biliary Atresia and Is Increased in Livers of Patients,” Gastroenterology 150, no. 1 (2016): 229–241.e5.

[160] M. Abd Allah, T. Zaalouk, G. Abo-Sheishaa, I. Shalash, and A. Bayoumy, “Role of IL-17A in Enhancing Liver Fibrosis Induced by TGF-β1 and IL-13 in Schistosoma mansoni Infected Mice,” Egyptian Journal of Immunology 29, no. 4 (2022): 174–183.

[161] J. L. Aparicio, M. Ottobre, M. Duhalde Vega, J. P. Coutelier, J. Van Snick, and L. A. Retegui, “Effects of Interleukin 17A (IL-17A) Neutralization on Murine Hepatitis Virus (MHV-A59) Infection,” European Cytokine Network 28, no. 3 (2017): 111–119.

[162] J. He, G. Lang, S. Ding, and L. Li, “Pathological Role of Interleukin-17 in Poly I:C-Induced Hepatitis,” PLoS One 8, no. 9 (2013): e73909.

[163] Y. Fan, W. Weifeng, Y. Yuluan, K. Qing, P. Yu, and H. Yanlan, “Treatment With a Neutralizing Anti-Murine Interleukin-17 Antibody After the Onset of Coxsackievirus b3-Induced Viral Myocarditis Reduces Myocardium Inflammation,” Virology Journal 8 (2011): 17.

[164] M. A. Saleh, A. E. Norlander, and M. S. Madhur, “Inhibition of Interleukin 17-A but not Interleukin-17F Signaling Lowers Blood Pressure and Reduces End-Organ Inflammation in Angiotensin II-Induced Hypertension,” JACC: Basic to Translational Science 1, no. 7 (2016): 606–616.

[165] L. Xue, K. Xie, X. Han, et al., “Detrimental Functions of IL-17A In Renal Ischemia-Reperfusion Injury In Mice,” Journal of Surgical Research 171, no. 1 (2011): 266–274.

[166] L. Ying, Y. Yao, H. Lv, et al., “IL-17A Contributes to Skeletal Muscle Atrophy in Lung Cancer-Induced Cachexia via JAK2/STAT3 Pathway,” American Journal of Physiology-Cell Physiology 322, no. 5 (2022): C814–C824.

[167] L. D. Roy, M. Sahraei, J. L. Schettini, H. E. Gruber, D. M. Besmer, and P. Mukherjee, “Systemic Neutralization of IL-17A Significantly Reduces Breast Cancer Associated Metastasis in Arthritic Mice by Reducing CXCL12/SDF-1 Expression in the Metastatic Niches,” BMC Cancer 14 (2014): 225.

[168] K. Zwerina, M. Koenders, A. Hueber, et al., “Anti IL-17A Therapy Inhibits Bone Loss in TNF-α-mediated Murine Arthritis by Modulation of the T-Cell Balance,” European Journal of Immunology 42, no. 2 (2012): 413–423.

[169] C. C. Chao, S. J. Chen, I. E. Adamopoulos, et al., “Anti-IL-17A Therapy Protects Against Bone Erosion in Experimental Models of Rheumatoid Arthritis,” Autoimmunity 44, no. 3 (2011): 243–252.

[170] A. W. Qiu, Q. H. Liu, and J. L. Wang, “Blocking IL-17A Alleviates Diabetic Retinopathy in Rodents,” Cellular Physiology and Biochemistry 41, no. 3 (2017): 960–972.

[171] Y. Zhu, W. Tan, A. M. Demetriades, et al., “Interleukin-17A Neutralization Alleviated Ocular Neovascularization by Promoting M2 and Mitigating M1 Macrophage Polarization,” Immunology 147, no. 4 (2016): 414–428.

[172] Y. T. Mohamed, A. Salama, M. A. Rabie, and M. A. Abd El Fattah, “Neuroprotective Effect of Secukinumab Against Rotenone Induced Parkinson's Disease in Rat Model: Involvement of IL-17, HMGB-1/TLR4 Axis and BDNF/TrKB Cascade,” International Immunopharmacology 114 (2023): 109571.

[173] X. Wang, X. Zhang, L. Sun, G. Gao, and Y. Li, “Protective Effect of Secukinumab on Severe Sepsis Model Rats by Neutralizing IL-17A to Inhibit IKBα/NFκB Inflammatory Signal Pathway,” European Journal of Medical Research 27, no. 1 (2022): 206.

[174] Q. Xu, J. Yu, X. Guo, et al., “IL-17A Promotes the Invasion-Metastasis Cascade via the AKT Pathway in Hepatocellular Carcinoma,” Molecular Oncology 12, no. 6 (2018): 936–952.

[175] T. G. Gergely, D. Kucsera, V. E. Tóth, et al., “Characterization of Immune Checkpoint Inhibitor-Induced Cardiotoxicity Reveals Interleukin-17A as a Driver of Cardiac Dysfunction After anti-PD-1 Treatment,” British Journal of Pharmacology 180, no. 6 (2023): 740–761.

[176] M. Shah, A. Maroof, P. Gikas, et al., “Dual Neutralisation of IL-17F and IL-17A With Bimekizumab Blocks Inflammation-Driven Osteogenic Differentiation of Human Periosteal Cells,” RMD Open 6, no. 2 (2020): e001306.

[177] F. Bai, H. Tian, Z. Niu, et al., “Chimeric Anti-IL-17 Full-Length Monoclonal Antibody Is a Novel Potential Candidate for the Treatment of Rheumatoid Arthritis,” International Journal of Molecular Medicine 33, no. 3 (2014): 711–721.

[178] H. Zhao, L. Shang, Y. Zhang, et al., “IL-17A Inhibitors Alleviate Psoriasis With Concomitant Restoration of Intestinal/Skin Microbiota Homeostasis and Altered Microbiota Function,” Frontiers in Immunology 15 (2024): 1344963.

[179] R. Teshima, N. Saito-Sasaki, and Y. Sawada, “Generalized Pustular Psoriasis and Systemic Organ Dysfunctions,” International Journal of Molecular Sciences 25, no. 11 (2024): 6270.

[180] A. Ogaya, K. Yamamoto, E. Okada, and Y. Sawada, “Sclerosing Cholangitis Exacerbated by Widespread Pustular Psoriasis,” Journal of Dermatology 51, no. 6 (2024): e216–e217.

RIGHTS & PERMISSIONS

2025 The Author(s). MedComm - Future Medicine published by John Wiley & Sons Australia, Ltd on behalf of Sichuan International Medical Exchange & Promotion Association (SCIMEA).